10.1002/ptr.2399 36 ImenshahidiM.HosseinzadehH
Retatrutide Regulatory Status Retatrutide occupies a unique position because it is not yet FDA-approved: Not FDA-approved currently in Phase 3 clinical trials with Eli Lilly No prescription pathway in the US yet no Mounjaro/Wegovy equivalent for retatrutide Legal as research chemical sold in the US for in-vitro and animal research under research-use-only labeling Likely to receive FDA approval in coming years if clinical trial endpoints meet expectations WADA status currently not specifically listed, though peptide hormones generally fall under WADA categories Not DEA-scheduled no controlled substance status Unlike semaglutide and tirzepatide, retatrutide does not yet exist as a prescription drug
Phentermine is approved for short-term use (a few weeks) in individuals with a BMI of 30 or higher or 27 or higher and weight-related conditions
This straightforward pricing model removes barriers to reaching your optimal weight-loss dose without worrying about sudden cost jumps
But costs born by public and private payers will be substantial near-term
Naturally produced by the body, peptides are essential for functions such as hormone regulation, immune defense, cellular communication, and tissue regeneration
